Sorry for this late update, but I'm on assignment Monday and Tuesday, so I won't be blogging. But I'm back on Wednesday-- and I'll see you then.
Questions? Comments? firstname.lastname@example.org
Biotech, which has been a market leader all year, is weak, with both the market-cap weighted IBB and equal weighted XBI down roughly 4 percent each.
The big question ahead of the Federal Reserve meeting this week is how the central bank will characterize the economy.
Competition alive and well in equity space.
Despite earnings, investors cannot help but notice the continuing impact of the strong dollar on tech revenues.
Three former U.S. Treasury Secretaries agree: The U.S. has plenty of problems, but it's still in a dominant position.
Gold surged amid market intrigue surrounding a deal between Venezuela and Citi to swap cash for part of the country's gold reserves.
It might soon be time to hand your money to the robots.